Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients
Hua Wang,1–3,* Liang Wang,1–3,* Yue Lu,1–3 Xiaoqin Chen,1–3 Qirong Geng,1–3 Weida Wang,1–3 Zhongjun Xia1–3 1Department of Hematological Oncology, 2State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Cen...
Main Authors: | Wang H, Wang L, Lu Y, Chen XQ, Geng QR, Wang WD, Xia ZJ |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-01-01
|
Series: | OncoTargets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/long-term-outcomes-of-different-bortezomib-based-regimens-in-chinese-m-peer-reviewed-article-OTT |
Similar Items
-
Dorsal Column Degeneration after Bortezomib Therapy in a Patient with Multiple Myeloma
by: Tatsuro Joh, et al.
Published: (2009-10-01) -
Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma
by: Farzaneh Ashrafi, et al.
Published: (2020-01-01) -
Treatment and prognostic factors for survival in newly diagnosed multiple myeloma patients with bortezomib and dexamethasone regimen: a single Chinese center retrospective study
by: Chen R, et al.
Published: (2017-08-01) -
Immune modulation therapy in the management of bortezomib-induced peripheral neuropathy
by: Jeter Ashley, et al.
Published: (2012-08-01) -
Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects
by: Elia Pancheri, et al.
Published: (2020-09-01)